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Finnish samples have been extensively utilized in studying single-gene disorders, where the founder effect has clearly aided in discovery,
and more recently in genome-wide association studies of complex traits, where the founder effect has had less obvious impacts. As the
field starts to explore rare variants’ contribution to polygenic traits, it is of great importance to characterize and confirm the Finnish
founder effect in sequencing data and to assess its implications for rare-variant association studies. Here, we employ forward simulation,
guided by empirical deep resequencing data, to model the genetic architecture of quantitative polygenic traits in both the general
European and the Finnish populations simultaneously. We demonstrate that power of rare-variant association tests is higher in the
Finnish population, especially when variants’ phenotypic effects are tightly coupled with fitness effects and therefore reflect a greater
contribution of rarer variants. SKAT-O, variable-threshold tests, and single-variant tests are more powerful than other rare-variant
methods in the Finnish population across a range of genetic models. We also compare the relative power and efficiency of exome array
genotyping to those of high-coverage exome sequencing. At a fixed cost, less expensive genotyping strategies have far greater power than
sequencing; in a fixed number of samples, however, genotyping arrays miss a substantial portion of genetic signals detected in
sequencing, even in the Finnish founder population. As genetic studies probe sequence variation at greater depth in more diverse pop-
ulations, our simulation approach provides a framework for evaluating various study designs for gene discovery.Introduction
A founder effect can result either from a true founder event
(i.e., the establishment of a new population from a limited
pool of individuals) or from an extreme reduction in
population size (i.e., a bottleneck in size) followed by
relative genetic isolation from other populations. The
population of Finland is one of the best-studied genetic
isolates. The Finnish genetic architecture has been shaped
by a series of founder effects and a subsequent drift in
local subisolates. The initial founder effects are generally
associated with two colonization waves 4,000 and 2,000
years ago to southern and western Finland. More
recently, there was an internal migration movement in
the 15th–16th centuries from a small southeastern area to
themiddle, western, and finally northern and eastern parts
of the country.1
The Finnish population has been extensively utilized in
genetic studies. It is considered to be a relatively homo-
genous large founder population and hence potentially
well suited for genetic mapping. The evidence of a founder
effect includes enrichment of almost 40 rare recessive
diseases, longer regions of linkage disequilibrium (LD),
increased kinship coefficients between pairs of randomly
chosen individuals, and extended runs of homo-
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Finland has been remarkably successful.1 Finnish samples
have also contributed to many genome-wide association
studies (GWASs) of complex traits, but because common
(minor allele frequency [MAF] > 5%) variation is less influ-
enced by human population history, a founder effect
would be less likely to provide a specific advantage in
this setting.
Studies of polygenic traits and disorders are nowmoving
to a middle ground between GWAS genotyping methods
(thus far focused largely on common variation, typically
MAF > 5%) and sequencing-based methods that were
most successfully employed for identifying extremely
rare variants in single-gene disorders. This middle ground
is association studies of lower-frequency (MAF < 5%) vari-
ants, analyzed either individually or in aggregate (the
aggregate analysis has also been termed the rare-variant
association study11). As such, it is of great interest and
importance to confirm the Finnish founder effect in
sequencing data that include rarer variants and to assess
the implications of these rare-variant association studies.
As a result of the founding event and subsequent strong
genetic drift, some variants that are rare in the ancestral
population will have risen in frequency in a founder pop-
ulation, whereas others will have decreased or disappeared.
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increase power of rare-variant tests in two ways. First, some
rare and potentially deleterious variants could rise to
higher frequencies, out of proportion to what might be
expected given their deleterious effects. Second, there is
greater homogeneity of rare variation in a founder popula-
tion and thus fewer background rare variants at any indi-
vidual locus. As an example, a protective mutation for
Alzheimer disease (MIM 104300) was discovered in part
because it has a much higher frequency in the Scandina-
vian populations (~0.4%) than in the general European
population (<0.01%).12
Exome sequencing studies are emerging as a popular
approach for identifying rare coding variants associated
with complex traits, whereas a cheaper alternative
approach is to use array-based genotyping of a defined
set of coding variants. The human genetics community
has aggregated an extensive list of putative functional
coding variants from the exome sequences of >12,000
individuals for array-based genotyping platforms (e.g.,
the Illumina Infinium HumanExome BeadChip and the
Affymetrix Axiom Exome Array Plate; see Exome Chip
Design in the Web Resources for a description of SNP
content and selection strategies). Although these arrays
do not provide a complete catalog of all coding variants,
the set of variants selected for array design is estimated to
include >97% of the nonsynonymous variants that would
be detected in any individual genome through exome
sequencing. In theory, the coverage would be even higher
for a founder population, which has fewer rare variants
than a nonfounder population.
To increase power to detect effects of rare variants, espe-
cially those that are too infrequent to be individually
tested for association, many groups have devised tests
that combine evidence across multiple variants.13 These
tests have become a standard approach for analyzing rare
variants and include burden tests14–16 and other types of
tests that aggregate evidence across sets of variants.17,18
The relative power of such tests to detect association is
strongly influenced by underlying genetic architecture.
Specifically, the proportion of causal variants among all
variants analyzed and the distribution of effect sizes and
allele frequencies of causal variants all affect test perfor-
mance. Different statistical tests also have different sets
of parameters, the values of which can have a large effect
on the power of the tests.
Different diseases and phenotypes most likely have
different architectures.19 To try to evaluate how different
sample selections (founder versus nonfounder popula-
tions), analytical methods (single-variant tests versus
gene-based tests), and study designs (exome sequencing
versus exome array genotyping) perform with different
genetic architectures, we have developed a population-
genetics framework to assess the impact of the Finnish
population history on genetic studies of rarer variation.
Our approach has four basic stages: (1) confirming and
characterizing the Finnish founder effect in sequence
data, (2) developing a simultaneous simulation ofThe Amsequence variation in the non-Finnish European (NFE)
population and the Finnish population to closely approx-
imate the sequence data, (3) specifying a range of models
of genetic architectures to generate simulated phenotypic
data, and (4) comparing operating characteristics of
different gene-based tests and single-variant tests on
phenotype, genotype, and sequence data from simulated
founder and nonfounder populations.
With this framework in place, we address the following
questions: (1) Under what types of genetic architecture(s)
is it more powerful to use a founder population such as
Finland? (2) Under different genetic models, what are the
optimal association tests for rare variants in a founder
population? (3) How does power compare between using
exome sequencing data and using exome chip data, partic-
ularly in a founder population? Our results show that
power to detect genetic signals—by both single-variant
and gene-based tests—is higher in samples from the
Finnish founder population than in equivalently sized
NFE samples, especially when the phenotypic effects of
variants are tightly coupled with effects on fitness. SKAT-O,
VT (variable-threshold) tests, and single-variant tests have
the highest mean power in a founder population across
simulated data sets. At a fixed cost, genotyping strategies
have far greater power than sequencing; in a fixed number
of samples, however, genotyping arrays miss a substantial
portion of causal variation detected in sequencing.Material and Methods
Empirical Exome Sequencing Data
We used whole-exome sequenced samples from the Genetics of
Type 2 Diabetes (GoT2D) Project. In total, 2,850 European type
2 diabetes case and control subjects from four cohorts (Diabetes
Genetics Initiative [DGI], Finland-United States Investigation of
NIDDMGenetics [FUSION], GoT2D-UK, and Kooperative Gesund-
heitsforschung in der Region Augsburg [KORA]) were whole-
exome sequenced at ~403. Exome target capture was performed
with the Agilent SureSelect Human All Exon hybrid selection kit,
and sequence was obtained on a HiSeq machine. Reads were
mapped to the human reference genome (hg19, UCSC Genome
Browser) with the Burrows-Wheeler Aligner20 and processed
with the Genome Analysis Toolkit (GATK) for recalibrating base-
quality scores and performing local realignment around known
insertions and deletions (indels).21 SNPs and small indels were
called with the UnifiedGenotyper module of GATK and filtered
for removal of SNPs with annotations indicative of technical arti-
facts (such as strand bias, low variant call quality, or homopolymer
runs).21 We kept samples from GoT2D-UK and KORA as the NFE
population and samples from FUSION (Table S1, available online)
as the Finnish population for our analyses. We excluded SNPs
with any missing data in any individual, SNPs with Hardy-Wein-
berg equilibrium p< 105, and all nonautosomal SNPs.We carried
out multidimensional scaling to identify population outliers
(Figure S1). We filtered out relatives for whom the estimated
genome-wide identity-by-descent (IBD) proportion to alleles
shared was >0.10. We also excluded individuals with an
inbreeding coefficient > 0.05 or < 0.05. We estimated IBDerican Journal of Human Genetics 94, 710–720, May 1, 2014 711
Figure 1. The Final Demographic Model for Simulating NFEs
and Finns Simultaneously
The NFEs were modeled as long-term (45,000 generations) con-
stant size (N ¼ 8,100) followed by a bottleneck (N ¼ 2,000) and
then by exponential growth (1.5% growth per generation). To
model the Finns, we tested three general classes of models, of
which only one (class 3 in Table S2) approximated the empirical
observations. In this model, after the initial founding event (100
generations ago, N ¼ 1,000), the Finns went through a slow
growth phase (0.5%–5% growth per generation) and then a
more recent fast growth phase (8%–30% growth per generation);
there was gene flow from the NFEs to the Finns.sharing by using PLINK’s ‘‘–genome’’ option22 and estimated
inbreeding coefficients by using PLINK’s ‘‘–het’’ option. All ana-
lyses were carried out on an LD-pruned set of SNPs obtained
with the PLINK option ‘‘–indep,’’ which recursively removes
SNPs within a sliding window. The parameters for –indep are as
follows: window size in SNPs¼ 50, n¼ 5 SNPs to shift the window
at each step, and variance-inflation-factor threshold ¼ 1.8. The
final data set included 843 Finnish samples and 820 NFE samples.
Ethics Statement
For the GoT2D study, attendance was voluntary, and each partic-
ipant provided written informed consent, including for informa-
tion on genetic analyses. Local institutional review boards
approved the study protocols.
Simulation of Exome Sequencing Data
Exome sequencing data were simulated with ForSim, a tool for
forward evolutionary simulation.23 The average gene coding
length was set to 1,500 bp. We used a mutation rate per site of
2 3 108,24–26 as well as a uniform locus-wide recombination
rate of 2 Mb/cM as previously reported.27 We modeled the distri-
bution of selection coefficients for de novo missense mutations
by a gamma distribution28 (as in previous reports,28,29 we assumed
that ~20% of missense sites are neutrally evolving).
For modeling the NFEs, we used a conventional four-parameter
model of the history of the European population with long-term
constant size followed by a bottleneck and then by an exponential
expansion (Figure 1).30 The four parameters used were (1) long-
term ancestral effective population size, (2) bottleneck population
size, (3) duration of exponential growth in generations, and (4)
recent effective population size. We adapted parameters from a
recent simulation that generated representative sequence data
for European populations.27 (See Figure 1 for final parameter
values.)712 The American Journal of Human Genetics 94, 710–720, May 1, 2We modeled the Finns as a founder population established by
a small number of NFEs. The founding event was followed by a
slow growth phase and a more recent fast growth phase (Figure 1).
We filtered the demographic-history parameters by comparing
them to empirical exome sequencing data. P(data j model) was
calculated and used for model fitting (see Appendix A for further
discussion). We tested two other models, neither of which agreed
with the empirical observations, as well as our current model
(Table S2).Simulation of Exome Chip Data
Exome chip data were generated on the basis of simulated exome
sequencing data. The process resembled that of the actual exome
chip design (see Web Resources for a description of SNP content
and selection strategies). Approximately 12,000 simulated exomes
across 16 cohorts were pooled together. The cohorts were matched
by ancestry and sample size with the real cohorts (except that non-
European samples were substituted with NFE samples). Only
missense variants observed three or more times in at least two
data sets were selected. Approximately 90% of the selected SNPs
passed the design and were used for the simulated chip. For simu-
lating the exome chip without contribution of Finnish samples, all
procedures were the same except that Finnish samples were re-
placed with an equal number of NFE samples.Simulation of Phenotypic Variation
We simulated a quantitative trait (QT) with a target size of 1,000
genes and heritability of 80%. For efficiency, we modeled the
heritability as completely explained by coding variants and a large
target size of 1,000 genes; power scales with total heritability, with
the fraction of heritability explained by coding variation, and
inversely with target size. We modeled additive genetic effects
and environmental effects. We did not consider nonadditive
effects (dominant, recessive, epistatic, or gene-environment inter-
actions) in our simulations. We used the joint allele frequency
spectrum of both the Finns and the NFEs when calculating herita-
bility. We scaled the effect sizes so as to cap heritability at 80%.
More specifically, variance explained by a variant was calculated
as 2 3 MAF 3 (1  MAF) 3 p2, where p is the phenotypic effect.
We summed this up over all variants and adjusted effect sizes of
all variants by a uniform factor to cap heritability (additive genetic
variance) at 80%.
We assume that neutral missense variants have no effect on
phenotype. To assign effect sizes of causal variants (nonneutral
missense variants), we implemented a range of possible mappings
between a variant’s selection coefficient (s)—we modeled the
distribution of selection coefficients for de novo missense muta-
tions by a gamma distribution, so s is known for every variant in
our simulated data—and its effect on phenotype (p). We modeled
these mappings as p ¼ st 3 (1 þ ε) as suggested by Eyre-Walker
et al.31 Here, t is the degree of coupling between p and s, and ε is
a normally distributed random-noise parameter. In the case of
common diseases of postreproductive onset, the role of natural
selection on causal variants is not yet clear. Therefore, we tested
a range of scenarios: M1 (t ¼ 0), M2 (t ¼ 0.5), M3 (t ¼ 1), and
M4 (t randomly chosen with equal probability among 0, 0.5,
and 1 for each effect gene).
To determing the direction of effect of causal variants on a QT,
we further assumed that, in each trait-affecting gene, 0%–20% of
the causal variants influence the QT in the opposite direction
from the remaining causal variants. This assumption is based on014
Figure 2. Empirically Observed Allele Frequency Spectra in 500
Finns and 500 NFEs
Means and SDs of proportions were calculated on the basis of 100
rounds of sampling. There was an excess of common variants in
the Finns for both synonymous (A) and missense (B) variants.two different arguments: (1) the vast majority of de novo amino
acid substitutions with a measurable effect reduce protein activity,
and gain-of-function alterations are much less frequent and are
restricted to specific residues or domains; and (2) some genes,
such as APOB (MIM 107730) and PCSK9 (MIM 607786),18,32
clearly illustrate a mixture of variants that affect QTs in both
directions.
Association Tests and Power Analysis
We conducted five different gene-based tests on simulated data.
We performed four burden tests—VT,14 T1 (fixed-threshold test
with a 1% threshold), T5 (fixed-threshold test with a 5%
threshold), and MB (Madsen and Browning)16—by running
SCORE-Seq (see Web Resources for details). In these tests, the
mutation information is aggregated across multiple variant sites
of a gene through a weighted linear combination and then related
to the phenotype of interest through appropriate regression
models. The weights can be constant (T1, T5, and VT tests) or
dependent on allele frequencies (MB test). The allele frequency
threshold can be fixed (T1, T5, and MB tests) or variable (VT
test). We also performed the unified optimal test SKAT-O by using
default weights.33 SKAT-O is a data-adaptive test that includes
both burden tests and the sequence kernel association test
(SKAT)17 as special cases. We carried out single-variant tests by
using PLINK’s ‘‘–linear’’ option.We limited our analysis to variants
with a MAF < 5%.
The exome-wide significance threshold for gene-based tests was
set to a ¼ 2.53 106 (after Bonferroni correction assuming 20,000
genes in the exome). Power was defined as the number of effect
genes reaching genome-wide significance divided by the target
size (1,000). The exome-wide significance threshold for single-
variant tests was 0.05 divided by the number of variants tested
(which varied with sample size, excluding singletons and double-
tons). The power of the single-variant test was defined as the
number of effect genes harboring genome-wide-significant vari-
ant(s) divided by 1,000.The AmResults
Assessing the Finnish Founder Effect
We analyzed whole-exome sequence data of NFE and
Finnish samples from the GoT2D Project (see Material
and Methods). If the Finnish population did indeed go
through a founding event in the past, there are a number
of direct predictions for the allele frequency spectra and
the sharing of variants between the Finns and the NFEs.
When comparing Finnish and NFE samples of the same
size (n ¼ 500), we found that the allele frequency spectra
were shifted toward higher frequencies in the Finns
(Figure 2). The proportion of singleton variants was
much lower in the Finns than in the NFEs (28% versus
46%, respectively, for synonymous variants; 39% versus
57%, respectively, for missense variants), whereas the
opposite was true for common (MAF > 5%) variants
(31% versus 22%, respectively, for synonymous variants;
19% versus 12%, respectively, for missense variants).
Furthermore, singleton variants in a population of Finns
(n ¼ 250) had a higher likelihood of being seen again in
another population of Finns (n ¼ 250) than did singleton
variants in a population NFEs of being seen again in
another population of NFEs (34% versus 23%, respectively,
for synonymous singleton variants, 30% versus 20%,
respectively, for missense singleton variants; Figure S2).
We also observed that SNPs found in both samples tended
to have higher frequencies in the Finns (paired t test p
value < 0.01; Table S3). Compared to the NFEs, the Finns
had a lower level of heterozygosity (on average, there
were 0.6% fewer heterozygous sites per individual in the
Finns, t test p value < 0.01) and reduced genetic diversity
(Watterson’s estimate adjusted by sequence length was
6.14 3 104 for the Finns and 1.01 3 103 for the NFEs).
All of these results strongly confirm the presence of a
founder effect in Finland.
Simulation of Coding-Sequence Variation in
Hundreds of Thousands of Samples
To enable a controlled characterization of the performance
of different sample selections, analytical methods, and
study designs under a range of scenarios, we used the for-
ward-simulation package ForSim23 to generate coding-
sequence data for the NFEs and the Finns simultaneously.
This way, we could simulate evolution of complex traits
over time in large samples and know the truth (i.e., fitness
effects) about all variants. To model the NFEs, we used the
conventional four-parameter model30 and adapted param-
eters from a recent simulation that generated representa-
tive sequence data for European populations (Figure 1).27
We further modeled the Finns as a founder population
established by a small number of NFEs. We refined our
demographic parameters for the Finnish model by
comparing to exome sequencing data from the GoT2D
project (see Material and Methods). In our final model,
the initial founding event was followed by a slow growth
phase and then a more recent fast growth phase witherican Journal of Human Genetics 94, 710–720, May 1, 2014 713
Figure 3. Agreement of Empirical Allele Frequency Spectra with
the Modeled Spectra
Sample sizes were 843 for the Finns and 820 for the NFEs. Synon-
ymous variants (A) and missense variants (B) are shown. Means
and SDs of proportions were calculated on the basis of 100 rounds
of sampling, and 1,000 genes were sampled for each round.gene flow from the NFEs to the Finns (Figure 1). Figure 3
shows that our final demographic model reproduces the
observed allele frequency spectra well. We also analyzed
the missense/synonymous ratio (Figure S3) and allele
sharing between the Finns and the NFEs (Figure S4); these
metrics are also similar between the observed and simu-
lated data.
Specification of a Range of Disease Models
Protein-coding variation will only partially explain the
phenotypic variation of any polygenic trait. However, to
focus on the role of coding variation (because it is more
likely to be enriched with functionally significant alleles),
we simulated a heritable QT (h2 ¼ 80%) for which aggre-
gated coding variation in each of 1,000 genes explains,
on average, 0.1% of total heritability. We assumed that
selectively neutral missense variants are background
variants with no effects on the trait, whereas selectively
nonneutral missense variants are the causal variants. We
generated four different disease models by varying the
degree of coupling (t) between a causal variant’s pheno-
typic effect and the strength of purifying selection against
that variant.31 Broadly, M1 (t ¼ 0) is characterized by rare
and common alleles that have similar effects on pheno-
type, M2 (t ¼ 0.5) produces a modest correlation between
variant frequency and effect size, andM3 (t¼ 1) results in a714 The American Journal of Human Genetics 94, 710–720, May 1, 2sharp inverse correlation. M4 (t randomly chosen among
0, 0.5, and 1 for each effect gene) might represent a more
realistic scenario, given that different genes are likely to
have different pleiotropic effects and are therefore exposed
to different strengths of purifying selection. As expected,
we observed that as t increased, more phenotypic variance
was explained by rare variants (Figure S5A).
Alterations in Allele Frequency in the Founder
Population
With simulated data, we demonstrated alterations in allele
frequency in the founder population, which could poten-
tially increase the power of rare-variant tests. First, there
was greater homogeneity of rare variation at any individual
locus in a founder population. The Finns had on average
2.53 fewer rare (MAF < 5%) variants per gene than did
the NFEs (mean 20.0 5 4.5 versus 52.3 5 7.4, respec-
tively). This reduction in rare variants was seen for both
variants we simulated as causal and those simulated as
neutral, background variants (Figure S6). As seen in
Figure S7, the cumulative allele frequency of causal
variants and background variants per gene was similar
between the Finns and the NFEs, meaning that there
were fewer rare variants in the Finns, but they were each
on average more common than variants in NFEs.
Second, there was increased frequency of causal variants
(thus variance explained per gene) at some genes. We
observed that the distribution of the variance explained
per gene was wider in the Finns than in the NFEs (Figure 4).
At one end of the distribution (the left tails of the graphs
in Figure 4), the increased frequency of some individual
causal variants led to a greater variance explained for
some genes in the Finns (this was more obvious with a
larger t); at the other end of the distribution, so many
causal variants were lost in Finland that other genes had
lower variance explained in the Finns. As a result, some
genes were detectable in smaller sample sizes in the Finns
than in the NFEs, whereas it was more difficult to detect
the effects of rare variation in some other genes, given
that too many causal variants had been lost because of
the founder effect.
Founder Population versus Nonfounder Population in
Exome Sequencing Studies
With simulated genotype and phenotype data, we
compared the power of using 30,000 NFEs and the power
of using 30,000 Finns in exome sequencing studies under
different disease models. We implemented five gene-based
tests (SKAT-O and the T1, T5, MB, and VT tests) and single-
variant tests. Because we are interested in the role of lower-
frequency variants, we ran all tests on variants with a MAF
< 5%. In the context of exome sequencing studies, the
significance threshold for calculating power was set to
a ¼ 2.5 3 106 (after Bonferroni correction assuming
20,000 genes in the exome).
As seen in Figure 5, as t increased, so did the relative in-
crease in power from using Finns in comparison to using014
Figure 4. Distribution of Variance
Explained per Gene
Distribution of variance explained per
gene by variants with a MAF < 5% under
four different disease models in either
30,000 Finns or 30,000 NFEs.
(A) M1 (t ¼ 0).
(B) M2 (t ¼ 0.5).
(C) M3 (t ¼ 1).
(D) M4 (t randomly sampled from 0, 0.5,
and 1 for each effect gene).NFEs (compare panels A, B, and C). Under M4, the biggest
power gain in the Finns was seen among genes for which
the t value was 1 (Figure S8). As the value of t increased,
the phenotypic impacts of rare variants increased
(Figure S5). Therefore, it is more powerful to use a founder
population in models where rare variation plays a more
prominent role. These results are consistent with the effect
of a founder event on allele frequencies—founder effects
have a greater impact on rare variants than on common
variants.
Understanding the Excess of Power in the Founder
Population
To understand why there was an excess of power in the
founder population across different disease models, we
considered genes detected in one population only. We
observed that genes detected only in the Finns tended to
have greater variance explained per gene in the Finns
than in the NFEs (Figure S9), whereas the opposite was
true for genes detected in the NFEs only (Figure S10). For
genes detected in the Finns only, the cumulative allele
frequency for background variants was similar between
the Finns and the NFEs, but the cumulative allele fre-
quency for causal variants was shifted upward in the Finns
(Figure S11). For genes detected in the NFEs only, the oppo-
site was true (Figure S12).
As shown above, the overall rise in frequency of causal
variants and thus the greater variance explained for some
genes could drive the power excess in the Finns. We
next tested whether reduced heterogeneity could alsoThe American Journal of Humacontribute to the power difference.
We selected a set of genes for which
the variance explained was closely
matched between the NFEs and the
Finns (Figure S13). As shown in
Figure S14, the accumulated allele fre-
quencies of causal variants and back-
ground variants were similar between
the two populations as well. The
power gain in the Finns was retained
under M3 (Figure S15), suggesting
that reduced genetic heterogeneity
alone could increase power when
variance explained at a gene stays
the same in the founder population.This effect was clearer when the t value was 1, given that
rare variants play a more prominent role.
Relative Power of Different Association Tests for Rare
Variants in a Founder Population
Among the five gene-based tests we conducted, SKAT-O
and the VT test performed best across a range of models
in both the Finns and the NFEs (Figures 5 and S16), given
that SKAT-O allows different variants to have different
directions and magnitude of effects and the VT test
decreases background noise by selecting an optimal fre-
quency threshold. The single-variant test performed
reasonably well under different disease models, and it
was particularly powerful when t was large, especially
when used in a founder population (Figures 5 and S16).
As t increased, the effect sizes of rare causal mutations
tended to increase, making it more powerful to test these
variants individually. For a founder population like the
Finns, as we have shown earlier, the allele frequency
spectra are shifted away from the rarest variants, which
gives extra power in testing rare variants individually.
Of note, LD was not taken into account in either the
single-variant or the gene-based tests. For gene-based tests,
LD was generally not addressed, at least for discovery of
gene-wide association signals. For single-variant tests, we
operated under the assumption that the causal variants
are directly assessed. Incorporating LD might have further
increased the power of single-variant analyses if one or
more very rare variants were tagged by a single more com-
mon variant.n Genetics 94, 710–720, May 1, 2014 715
Figure 5. Power of Exome Sequencing Studies in 30,000 Finns
versus 30,000 NFEs
We simulated a QT (h2 ¼ 80%) for which aggregated coding vari-
ation in 1,000 genes explains the total heritability. We generated
models M1–M4 by varying the degree of coupling (t) between a
causal variant’s phenotypic effect and the strength of purifying se-
lection against that variant. We compared SKAT-O, the VT test,
and single-variant tests (singleVar). For each model, means and
SDs of power were calculated on the basis of 20 simulated data sets.
(A) M1 (t ¼ 0).
(B) M2 (t ¼ 0.5).
(C) M3 (t ¼ 1).
(D) M4 (t randomly sampled from 0, 0.5, and 1 for each effect
gene).
Figure 6. Power of Exome Chip Study versus Exome Sequencing
Study in the Finns
The comparison was done under M4 with SKAT-O. Because
different genes are likely to have different pleiotropic effects
and are therefore exposed to different strengths of purifying se-
lection, M4 was generated to represent a potentially more realistic
scenario. The top two lines show power comparison at a fixed
sample size; the bottom two lines show power comparison at a
fixed cost (and thus only one-tenth of the samples were
sequenced). For both exome chip and exome sequencing studies,
means and SDs of power were calculated on the basis of 20 simu-
lated data sets.Exome Chip Studies versus Exome Sequencing Studies
Exome chip genotyping, despite being a much cheaper
technology than exome sequencing, has not been rigor-
ously assessed in terms of cost efficiency. Here, we used
our simulation framework to try to address this question.
We first confirmed that our simulations reproduced the
expected differences in observed allele frequency spectra
between exome chip and exome sequence data (compare
Figures S17 and 3B). We then compared the cost efficiency
of exome chip studies and exome sequencing studies un-
der different disease models in the Finnish founder popu-
lation. The cost of exome chip per sample was assumed to
be about one-tenth of that of exome sequencing. Figure 6
shows that under M4, the power of SKAT-O was far greater
in exome chip studies than in exome sequencing studies
at a fixed cost (middle versus bottom line); in a fixed num-
ber of samples, however, genotyping arrays missed a sub-
stantial portion of causal variation detected in sequencing
(top versus middle line). We also compared the two study
designs in a nonfounder population (Figure S18) under
M1–M3 (Figures S19 and S20), as well as by using different
rare-variant association tests (Figure S19), and observed
similar results. Despite substantial cost efficiency, the
exome chip was underpowered to detect the contribu-716 The American Journal of Human Genetics 94, 710–720, May 1, 2tions of certain genes simply because not enough causal
variants in these genes were covered by the chip. This
became more apparent as t increased (Figure S20), because
the allele frequency spectrum of causal variants shifted
downward, and the exome chip captured fewer casual var-
iants (Figure S21).
Because Finnish samples contributed to exome chip
design, we went on to assess how much their inclusion
would affect the power of the exome chip in Finns, i.e.,
how the exome chip would perform in a non-Finnish
founder population. To address this question, we simu-
lated a different exome chip with no contribution of
Finnish samples (replaced with an equal number of NFE
samples). As expected, the power for rare-variant associa-
tion in Finns decreased when Finns were not used in the
SNP-discovery process of the exome chip. The power
decrease was minimal at a low sample size, reaching a dif-
ference of approximately 2% when 30,000 samples were
used (Figure S22; the power dropped from ~10% to ~8%
when Finns were not used). This suggests that the current
exome chip would perform slightly less well in a non-
Finnish founder population. However, the exome chip
is still a far more cost-efficient strategy for such popula-
tions than exome sequencing, the power of which is
negligible at a comparable cost (bottom line in Figure 6).
If it is desirable to avoid the marginal loss of power in
non-Finnish founder populations of interest, one could
perform exome sequencing by using a representative pop-
ulation sample first and supplement the exome chip with
the newly discovered variants to ensure that rare variation014
in that founder population is directly represented on
the chip.Discussion
By using forward simulations based on empirical deep rese-
quencing data, we have shown that (1) founder popula-
tions can provide additional power, especially when the
phenotypic effects of variants are tightly coupled with
effects on fitness; (2) in a founder population, the single-
variant test, SKAT-O, and the VT test perform best under
different disease models, and the single-variant test is
particularly powerful when the phenotypic effects of vari-
ants are tightly coupled with effects on fitness; and (3)
exome chip genotyping is currently much more cost effi-
cient than exome sequencing but misses a substantial
portion of causal variation in a sequencing study of the
same sample size. We also suggest that more than 10,000
samples will most likely be required for reaching nonnegli-
gible statistical power to identify associations with low-
frequency variation (under the assumption of a per-gene
contribution of ~0.1% of heritability). This is consistent
with recent independent estimates of required sample
sizes.11,34 We are almost certainly underestimating the
required sample size, given that we modeled a highly
heritable trait for which all heritability is explained by
coding variants in 1,000 genes, whereas the average contri-
bution of coding variation to heritability is most likely
typically lower than 0.1% per gene.
The changes in allele frequency and decreased allelic
diversity in founder populations caused by the bottleneck
event(s) and drift can aid in the detection of rare-variant
associations. We have shown through our simulation
that the power gain in the founder population is from
both increased frequency of causal variants (thus variance
explained per gene) at some genes and reduced genetic
heterogeneity. Founder populations typically also demon-
strate a higher degree of cultural and environmental
homogeneity (not modeled here), which could further
increase the strength of the genetic signals. However, there
are also limitations with using founder populations. First,
the population size might not be large enough to allow
for the collection of sufficiently large numbers of cases.
Second, rare variants might be recent in origin and hence
specific to a single founder population; these are the vari-
ants that are potentially the least replicable, although
this concern is less relevant for gene-based ‘‘burden’’-type
tests where variants are aggregated. Of note, the variants
might be unique to founder populations, but the finding
of genes is relevant to all populations. Third, a higher
rate of direct and cryptic relatedness in some founder
populations could confound baseline assumptions of in-
dependence among genotypes and phenotypes, and
accounting for this sample structure could require more
specialized approaches. Fourth, there might not be enough
power to detect some genes in the founder population as aThe Amresult of the loss of causal variants (Figure 4). Nevertheless,
the increased power, particularly for single-variant tests,
suggests that exome chip and/or exome sequencing in all
available samples from founder populations would be an
efficient use of resources. Different founder populations
will happen to be better powered for different genes (in
each population, certain genes will gain power, whereas
others will lose power, but the genes that gain power will
vary across populations). Thus, a potentially attractive
strategy for rare-variant studies is to employ a diverse panel
of well-powered founder populations.
We evaluated a variety of statistical tests that were
developed under different assumptions about genetic
architecture. We have shown that these tests are indeed
sensitive to different disease models. SKAT-O and the VT
test outperformed the other gene-based tests across a range
of different genetic architectures. It is also worth noting
that single-variant tests performed as well as or better
than SKAT-O and the VT test, particularly in founder
populations with decreased allelic diversity. This raises as
one possible strategy the use of single-variant tests as a
screen in founder populations and then follow-up with
candidate-gene sequencing.
We have shown that exome chip genotyping studies
are currently much more cost efficient than exome
sequencing studies under a range of genetic models. In a
fixed number of samples, however, exome chip genotyping
studies miss a substantial portion of causal variation that
could be detected by sequencing. Continued sharp drops
in the cost of sequencing and/or targeted sequencing to
follow up initial results might enable better-powered and
more cost-efficient exome sequencing or whole-genome
sequencing studies. Given the requirement for large sample
sizes, the ability to combine studies, for example, in meta-
analyses will be critical for a new wave of discoveries. Of
note, as reference panels for imputation become larger
and represent more populations, imputation of rare vari-
ants into samples with existing genotype data is another
likely complementary approach for future studies.
Our study has a number of limitations. We have taken a
forward-in-time approach for simulating population
sequence data, which has substantial advantage in terms
of being able to model different genetic architectures and
demographic parameters, but this approach comes with
the cost of requiring greater computational resources.
Because of this limitation, as well as the complexity of
the demographic models, we did not do a complete search
through the entire parameter space for the best-fitting
demographic model. Another limitation with our simula-
tion is that the limited sample size of the empirical data
provided an incomplete view of rare variants in the popu-
lation, so our simulations might not be completely accu-
rate at very low allele frequencies. Moreover, as suggested
by Casals et al.,35 there might be a relaxation of selection
in the founder population, which we did not consider in
our simulation. It is also worth noting that our empirical
Finnish samples are from all across Finland (Table S1),erican Journal of Human Genetics 94, 710–720, May 1, 2014 717
and therefore our model for simulating the Finns ignores
the demographic heterogeneity within Finland. As deeper
and richer human genetic data become available, the
models can be calibrated and improved. Last, but not least,
our study did not explore the effects of properties such as
gene size or mutation rate on power, nor did it characterize
the power of rare-variant tests at noncoding loci, where
causal-variant frequencies and effect sizes might be
different.
In summary, our study has highlighted the usefulness
of understanding the population-genetic properties of a
study population to explore a range of genetic models
and recognize the features and limitations of different
association study designs in that population. As the field
of human genetics moves forward to explore new and
expanded sources of variation, such models offer a context
in which researchers can interpret the data and plan future
studies for gene discovery. With current approaches
focused on rare variation, our work suggests that founder
populations such as Finland can play an important role
in genetic studies.Appendix A: Fitting Finnish Demographic-History
Parameters
P(datajmodel) for each model was calculated as below. The
first two terms are the probabilities of the observed allele
frequency spectra of synonymous and missense variants
given the demographic model being tested. The third
term is the probability of the observed synonymous/
missense ratio. The last two terms calculate the probabili-
ties of the observed allele sharing between Finns and NFEs.
Pðdata jmodelÞ¼
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Abbreviations are as follows: s and m, observed total
number of synonymous and missense variants, respec-
tively; si and mi, observed number of synonymous and
missense variants, respectively, in the ith frequency cate-
gory; pi, predicted proportion of synonymous variants in
the ith frequency category among all synonymous variants;
qi, predicted proportion of missense variants in the i
th
frequency category among all missense variants; ri,
predicted proportion of synonymous variants in the ith fre-
quency category among all variants (both synonymous
and missense) in the ith frequency category; ssi and smi,
observed number of synonymous and missense variants,
respectively, in the ith frequency category in the Finns
and shared with NFEs; xi and yi, predicted proportion718 The American Journal of Human Genetics 94, 710–720, May 1, 2of synonymous and missense variants, respectively,
within the ith frequency category in the Finns and shared
with NFEs.Supplemental Data
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